New Treatment Options for Patients With Bladder Cancer

Presented by:
Thomas W. Flaig
Search for other papers by Thomas W. Flaig in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 20: Issue 5.5
Online Publication Date:
02 Jun 2022
DOI:
https://doi.org/10.6004/jnccn.2022.5019
Restricted access

Bladder cancer is not rare—in men, it is the fourth most common cancer and the eighth leading cause of cancer-related death. The emergence of new systemic therapies, approval of PD-1 and PD-L1 inhibitors, and progress in the development of biomarkers have revolutionized the treatment of this urologic malignancy. The current NCCN Guidelines, which reflect the most up-to-date, evidence-based data relating to the evaluation and management of bladder cancer, support the incorporation of some of these novel therapeutics into clinical practice.

Disclosures: Dr. Flaig has disclosed receiving grant/research support from Agensys, Inc., Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Inc., Janssen Pharmaceutica Products, LP, Merck & Co., Inc., sanofi-aventis U.S., and Seattle Genetics, Inc; serving as a scientific advisor for Janssen Pharmaceutica Products, LP, and Seattle Genetics, Inc.; and receiving equity interest/stock options in and intellectual property rights for Aurora Oncology.

Correspondence: Thomas W. Flaig, MD, University of Colorado, Mail Stop F520, 13001 East 17th Place, Aurora, CO 80045. Email: thomas.flaig@cuanschutz.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33.

  • 2.

    Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214–218.

  • 3.

    Flaig TW, Spiess PE, Abern M, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Bladder Cancer. Version 1.2022. Accessed March 31, 2022. Available at NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22:919–930.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Gill J, Prasad V. Pembrolizumab for non–muscle-invasive bladder cancer—a costly therapy in search of evidence. JAMA Oncol 2021;7:501–502.

  • 6.

    Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 2020;203:902–909.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–1026.

  • 8.

    Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384:2102–2114.

  • 9.

    Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383:1218–1230.

  • 10.

    Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384:1125–1135.

  • 11.

    Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39:2474–2485.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381:338–348.

Copyright:
Copyright © 2022 by the National Comprehensive Cancer Network 2022
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 May 2022
Online Publication Date:
02 Jun 2022

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2883 418 98
PDF Downloads 1696 136 8
EPUB Downloads 0 0 0